Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... disease risk, according to the study. Treatment with the oral diabetes drug metformin reduced the rate of developing diabetes by 18 percent after 10 years compared with ...
Subject: NIH/National Institute of Diabetes and Digestive and Kidney Diseases
2009 NOV 16 ... in combination with chemotherapy." "Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transformation and selectively kills ...
2009 NOV 16 ... weeks), the treatment effects of JANUMET (a fixed-dose combination of sitagliptin and metformin) and metformin as initial therapy were compared. In the ...
2009 NOV 23 ... New Drug Application (ANDA) with the FDA for a generic version of GLUMETZA® (metformin hydrochloride extended release tablets), 500 mg and 1000 mg strengths. ...
2009 NOV 9 ... arrangement with Merck for fixed dose combinations of sitagliptin and extended release metformin entered into in July 2009. Revenue for the three months ended September 30, 2008 ...
2009 NOV 16 ... treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of ≤7 ...
2009 NOV 23 ... we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy," scientists writing in the New U.K. Journal of Medicine ...
2009 NOV 9 ... "Insulin is recommended as a second-line treatment after diet and metformin fall to reach and/or maintain glycemic targets considered to minimize the risk for ...
2009 NOV 9 ... secretion and may influence their systemic plasma concentrations and extrarenal effects. Metformin, used for treatment of type 2 diabetes, is taken up into renal tubular cells by the ...
2009 NOV 2 ... metabolism being a likely contributor. We aimed to assess noninvasively the efficacy of metformin and rosiglitazone monotherapy in normalizing myocardial substrate metabolism in an ...
2009 NOV 2 ... the National Institutes of Health (NIH) Obesity Treatment Guidelines. Phendimetrazine, metformin, and phentermine Plus L-5-hydroxytryptophan (5-HTP) with carbidopa were all used more ...
2009 NOV 9 ... by a quantitative morphometric analysis in 43 males with type 2 diabetes under metformin alone (22 cases) or associated with rosiglitazone (21 cases) and in 22 control ...
2009 NOV 9 ... According to recent research from the United States, "To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by ...
2009 NOV 23 ... including the insulin secretagogues and sensitizers, can lead to weight gain, except for metformin, which is weight-neutral. Among the newer agents, the dipeptidyl peptidase-4 inhibitors ...
2009 NOV 17 ... in ovaries with functional and regressing corpora lutea (CL) and the action of metformin in preventing these possible alterations using a mouse model. To obtain a CL functional ...
2009 NOV 9 ... of pioglitazone vs. placebo in patients with Type 2 diabetes treated with combined metformin-sulphonylurea therapy in the PROspective pioglitAzone Clinical Trial In macroVascular ...
2009 NOV 23 ... and insulin, improve glycemic control but are associated with weight gain or, as with metformin, are weight-neutral or weight-sparing. The incretin-based therapies, such as the ...
2009 NOV 2 ... (DM) can begin early in the progression from impaired glucose tolerance to type 2 DM. Metformin is recommended as initial drug therapy for managing hyperglycemia in type 2 DM," ...
